- Companies
- Athelas
Athelas Acquisition, Valuation, Funding & Investors
Athelas was acquired by Commure in October 2023.
Athelas revenue at acquisition
$100M
Last twelve months · Oct 2023
Cumulative funding Athelas raised
$150M
across 5 funding rounds
Key investors in Athelas
Sequoia Capital
Y Combinator
Initialized Capital
Tribe Capital
Human Capital
Fifty Years
About Athelas
Athelas is a healthcare technology company that sells revenue cycle management services, an AI-native electronic health record, ambient AI clinical notes, voice agents and practice management software to medical practices and health systems. It was founded in 2016 by Tanay Tandon and Deepika Bodapati, went through Y Combinator, and began with a smartphone-linked device that returns a white blood cell count from a small blood sample. The company later expanded into remote patient monitoring before focusing on administrative automation for providers. It earns revenue from software subscriptions and managed billing services. In October 2023 it merged with Commure, and it now operates as a Commure company based in Mountain View, California.
Founded
2016
HQ
Website
Status
Acquired
Customer focus
B2B
Revenue model
Subscription, Usage-based
Revenue
$100M (Oct 2023)
Valuation
$1.5B (Jan 2022)
Athelas Acquisition
Athelas was acquired by Commure for an undisclosed price on 4 October 2023.
Before the acquisition Athelas had raised $150M across 5 funding rounds.
Commure and Athelas announced on 4 October 2023 that they would merge, with Athelas chief executive Tanay Tandon leading the combined company as chief executive, Deepika Bodapati as chief operating officer and Dhruv Parthasarathy as chief technology officer. General Catalyst provided fresh capital that valued the combined company at 6 billion dollars. Athelas brought revenue cycle management and remote patient monitoring products used by thousands of providers, and processed hundreds of millions of dollars in healthcare claims. Commure supplied enterprise software to large health systems including HCA Healthcare, Jefferson and Providence. The companies said they expected the combination to speed up revenue cycle automation and workflow tools for hospitals. The combined company became the platform for later purchases such as Augmedix and Memora Health.
| Acquirer | Date | Type |
|---|---|---|
| 4 Oct 2023 | Strategic M&A |
Sources: athelas.com, healthcareittoday.com
Athelas Valuation
Athelas is currently valued at $1.5B, based on its Series C in January 2022. Read the announcement ↗
The $59M round was led by Tribe Capital, with participation from Greenoaks, Y Combinator, Initialized Capital, Human Capital, Fifty Years and 1 other investor.
Athelas' valuation has moved from $1.5B at its Series B in August 2021 to $1.5B in January 2022, across 2 priced rounds.
Athelas valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Jan 2022 | Series C | $1.5B |
| Aug 2021 | Series B | $1.5B |
Athelas Funding History
Athelas has raised a total of $150M across 5 funding rounds.
Athelas' first fundraising round was a $125K pre-seed round in January 2016. The most recent completed round was a $59M Series C in January 2022.
Athelas funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jan 2022 | Series C | Tribe Capital (lead); Greenoaks; Y Combinator; Initialized Capital; Human Capital; Fifty Years; Sequoia Capital | $59M | $1.5B | Tribe Capital led the second of two consecutive rounds in Athelas, announced on 31 January 2022, with investment from Sequoia Capital, Y Combinator, Greenoaks, Human Capital and Initialized Capital. Arjun Sethi of Tribe Capital joined the company as a board observer. Athelas provides remote patient monitoring to hospitals, health systems and small practices and reported serving more than 40,000 patients with chronic conditions. It was founded in 2016 by Tanay Tandon and Deepika Bodapati and merged with Commure in October 2023. |
| Aug 2021 | Series B | General Catalyst (lead); Human Capital; Tribe Capital; Adam Guild | $72M | $1.5B | General Catalyst led a US$72 million round in Athelas in 2021, the first of two consecutive rounds that together raised more than US$132 million and were announced on 31 January 2022. Tribe Capital led the second round, and Sequoia Capital, Y Combinator, Greenoaks, Human Capital and Initialized Capital invested across the rounds. The financing valued the company at about US$1.5 billion. Athelas said it was the fastest-growing remote patient monitoring platform in the United States, serving hospitals, health systems and small practices, and it reported serving more than 40,000 patients with chronic conditions. The proceeds were to fund product development and the growth of its remote monitoring service. Athelas was founded in 2016 by Tanay Tandon and Deepika Bodapati, and its remote monitoring and blood testing devices grew from a hackathon project. The company merged with Commure in October 2023. |
| Feb 2019 | Series A | Georges Harik (lead); Fifty Years; Sequoia Capital | $15M | - | Athelas raised US$15 million in a Series A round in February 2019, led by Georges Harik, with Sequoia Capital and Fifty Years also recorded as investors. It followed a US$3.7 million seed round led by Sequoia Capital in August 2017. At the time Athelas was building its at-home blood testing device, which returns a white blood cell count and related cell counts from a small blood sample using machine learning. The company was founded in 2016 by Tanay Tandon and Deepika Bodapati and went through Y Combinator. It later grew into remote patient monitoring, revenue cycle management and healthcare software, and it merged with Commure in October 2023. |
| Aug 2017 | Seed | Sequoia Capital (lead); Liquid 2 Ventures; Initialized Capital | $4M | - | Athelas, a Silicon Valley startup, announced on 28 August 2017 that it had raised US$3.7 million in a seed round led by Sequoia Capital, with participation from Initialized Capital and Liquid 2 Ventures. The company introduced a countertop device paired with a smartphone app that returns a white blood cell count, neutrophils, lymphocytes and platelets from a small blood sample in about 60 seconds, using machine learning to compare the sample against thousands of cell images. Athelas had published papers on the accuracy of its data and said the kit would need further approval before it could be sold over the counter. It was founded in 2016 by Tanay Tandon and Deepika Bodapati and went through Y Combinator. The business later moved into remote patient monitoring and healthcare software and merged with Commure in October 2023. |
| Jan 2016 | Pre-seed | Y Combinator | $125K | - | Y Combinator invested US$125,000 in Athelas in 2016 when the company joined the accelerator. Athelas was founded in 2016 by Tanay Tandon and Deepika Bodapati and was building an at-home blood testing device that returns a white blood cell count from a small blood sample using machine learning. The accelerator investment preceded the US$3.7 million seed round led by Sequoia Capital in August 2017. Athelas later grew into remote patient monitoring, revenue cycle management and healthcare software and merged with Commure in October 2023. |
Who has invested in Athelas?
11 investors have backed Athelas across its funding rounds, including Sequoia Capital, Y Combinator, Initialized Capital, Tribe Capital, Human Capital and Fifty Years.
Lead investors include Tribe Capital, General Catalyst, Georges Harik and Sequoia Capital.
Athelas Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | Aug 2017 | ||
| 2 | Participant | Jan 2016 | ||
| 2 | Participant | Aug 2017 | ||
| 2 | Participant | Aug 2021 | ||
| 2 | Participant | Feb 2019 | ||
| 2 | Lead | Aug 2021 | ||
| 1 | Lead | Aug 2021 | ||
| 1 | Participant | Jan 2022 | ||
| 1 | Lead | Feb 2019 | ||
This data is available for Pro users. Sign up to see all 11 Athelas investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAthelas Competitors
Athelas competitors include listed companies like JMDC, Molbio Diagnostics and Certara, and private ones like Noom, WeDoctor and MindMaze.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $320M | $87M | $1.5B | 4.6x | ||
| Private | $400M | - | $3.7B | 9.3x | ||
| Private | $267M | - | $7B | 50.4x | ||
| Private | - | - | $1.5B | - | ||
| Publicly listed | $149M | $34M | $1.5B | - | ||
| Publicly listed | $419M | $103M | $1.7B | 4.7x |
Athelas Public Comps
Athelas is no longer listed, but its public comps include Beijing Balance Medical, Sinocare, Indegene, Edge Medical, Nakanishi, Ping An Healthcare, JMDC, Medartis, NovoCure and Savaria.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $93M | $37M | 16.1x | - | 40.3x | - | |||
| $700M | $43M | 2.2x | 2.0x | 35.6x | 15.2x | |||
| $369M | $68M | 3.7x | 3.1x | 19.8x | 17.7x | |||
| $68M | ($10M) | 18.3x | 10.6x | (122.6x) | 132.9x | |||
| $515M | $53M | 2.6x | 2.3x | 25.2x | 8.6x | |||
| $822M | $52M | 0.7x | 0.7x | 10.4x | 14.6x | |||
| $320M | $87M | 5.1x | 4.6x | 18.9x | 17.9x | |||
| $327M | $54M | 5.2x | 4.2x | 31.3x | 23.5x | |||
This data is available for Pro users. Sign up to see all Athelas competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Athelas
| When was Athelas founded? | Athelas was founded in 2016. |
| Where is Athelas headquartered? | Athelas is headquartered in Mountain View, United States. |
| Is Athelas publicly listed? | No, Athelas was acquired by Commure in October 2023. |
| Who acquired Athelas? | Athelas was acquired by Commure in October 2023. |
| What is Athelas' valuation? | Athelas was last valued at $1.5B in its Series C in January 2022. |
| How much funding has Athelas raised? | Athelas has raised $150M across 5 funding rounds. |
| What was Athelas' last funding round? | Athelas' last funding round was a $59M Series C in January 2022, led by Tribe Capital. |
| Who are Athelas' investors? | Athelas' investors include Sequoia Capital, Y Combinator, Initialized Capital, Human Capital, Fifty Years, Tribe Capital, General Catalyst, Greenoaks, Georges Harik, Liquid 2 Ventures and 1 other. |
| Which companies are comparable to Athelas? | Companies comparable to Athelas include JMDC, Noom, WeDoctor, MindMaze, Molbio Diagnostics and Certara. |
See companies similar to Athelas
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




